Axinix 1MG & 5MG (Axitinib)
Product Name : Axinix (Axitinib)
Generic Name : Axitinib
Formulation : Tablet
Available Pack Size : 180’s Pot & 60’s Po
Available Strengths : 1 mg & 5 mg
Registrations : 08.07.2021
Product Information
Axinix (Axitinib) 1mg and 5mg is a potent and selective second-generation inhibitor of Vascular Endothelial Growth Factor Receptors VEGFR-1, VEGFR-2, and VEGFR-3 used to treat advanced Renal Cell Carcinoma (RCC) in adult patients. It works by selectively blocking the tyrosine kinase activity of VEGF receptors, thereby inhibiting tumour angiogenesis, the process by which cancers develop new blood vessels to fuel their growth and spread. Manufactured by Beacon Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Axinix (Axitinib) 1mg and 5mg
| Brand Name | Axinix (Axitinib) |
| Generic Name | Axitinib INN |
| Drug Class | Selective Second-Generation VEGFR Tyrosine Kinase Inhibitor (VEGFR-1, VEGFR-2, and VEGFR-3 Inhibitor) |
| Available Strengths | 1mg and 5mg |
| Formulation | Film-Coated Tablet |
| Pack Size | 180 Tablets per Pot and 60 Tablets per Pot |
| Primary Indication | Advanced Renal Cell Carcinoma (Kidney Cancer), including First-Line Combination Therapy and Second-Line Monotherapy |
| Regulatory Approvals | Originator molecule USFDA Approved and EMA Approved for advanced Renal Cell Carcinoma (as monotherapy after one prior systemic therapy and in combination with immune checkpoint inhibitors for first-line treatment). |
| Originator Brand | Inlyta by Pfizer |
| Manufacturer | Beacon Pharmaceuticals Ltd., Mymensingh, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration Date | 08/07/2021 |
| Storage Conditions | Store at 20 to 25 degrees Celsius (excursions permitted between 15 and 30 degrees Celsius). Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Axinix (Axitinib) Works
Axinix contains Axitinib, a potent and selective second-generation tyrosine kinase inhibitor that targets Vascular Endothelial Growth Factor Receptors VEGFR-1, VEGFR-2, and VEGFR-3. These receptors sit on the surface of blood vessel cells and play a central role in angiogenesis, the biological process through which tumours recruit new blood vessels to supply themselves with oxygen and nutrients. In renal cell carcinoma and other highly vascular cancers, this angiogenic pathway is a primary driver of tumour growth and metastasis.
Axitinib works by binding to the intracellular tyrosine kinase domain of VEGFR-1, VEGFR-2, and VEGFR-3 at therapeutically relevant concentrations, blocking the phosphorylation and downstream signalling that triggers new blood vessel formation. By starving the tumour of its blood supply, Axinix slows tumour growth, limits the spread of cancer to distant sites, and can cause existing tumour blood vessels to regress.
Compared with earlier anti-angiogenic agents, Axitinib is highly selective for the VEGF receptor family, with minimal off-target activity against unrelated kinases. This selectivity contributes to a more predictable side-effect profile. Axinix is taken as an oral tablet twice daily, offering patients an effective and convenient treatment option as monotherapy or in combination with immune checkpoint inhibitors.
Indications for Axinix (Axitinib)
Axinix (Axitinib) is indicated for the following conditions:
|
Advanced Renal Cell Carcinoma After One Prior Systemic Therapy For adult patients with advanced renal cell carcinoma (kidney cancer) after failure of one prior systemic therapy, such as sunitinib or a cytokine-based regimen. In this setting, Axitinib is used as a single-agent monotherapy. |
First-Line Advanced RCC in Combination with Pembrolizumab Axitinib in combination with the immune checkpoint inhibitor Pembrolizumab (anti-PD-1) is approved as a first-line treatment for adult patients with advanced renal cell carcinoma. This combination has demonstrated significant improvements in overall survival, progression-free survival, and objective response rate compared with standard single-agent therapy. |
|
First-Line Advanced RCC in Combination with Avelumab Axitinib in combination with the immune checkpoint inhibitor Avelumab (anti-PD-L1) is also approved as a first-line treatment for adult patients with advanced renal cell carcinoma, offering another immunotherapy-based combination approach with proven efficacy in clinical trials. |
Anti-Angiogenic Mechanism Across RCC Subtypes Renal cell carcinoma is a highly vascular cancer that depends heavily on new blood vessel formation. Axitinib’s selective VEGFR inhibition makes it particularly effective against this tumour type, cutting off the blood supply that sustains cancer growth and progression. |
Benefits of Axinix (Axitinib) 1mg and 5mg
|
Highly Selective VEGFR Inhibition Axinix is one of the most selective inhibitors of VEGFR-1, VEGFR-2, and VEGFR-3, targeting the primary angiogenic pathway that drives renal cell carcinoma growth with minimal off-target kinase activity, contributing to a more manageable side-effect profile. |
Proven Combination with Immunotherapy When combined with immune checkpoint inhibitors such as Pembrolizumab or Avelumab, Axitinib has demonstrated superior overall survival and progression-free survival compared with standard monotherapy, making it a cornerstone of modern first-line RCC treatment. |
Individualised Dose Titration Available in 1mg and 5mg strengths, Axinix allows oncologists to start at the standard dose and titrate upward or downward based on individual patient tolerability and blood pressure response, maximising efficacy while managing side effects. |
|
Affordable Alternative to Inlyta Axinix contains the same active ingredient as Inlyta by Pfizer, at a significantly lower cost. This makes long-term targeted cancer treatment financially accessible for patients in developing and developed countries alike, without compromising on quality. |
Convenient Oral Administration Taken orally twice daily, Axinix provides patients with a tablet-based treatment regimen that eliminates the need for hospital-based intravenous infusions for the anti-angiogenic component of their therapy, reducing treatment burden and improving quality of life. |
WHO-GMP and cGMP Certified Produced by Beacon Pharmaceuticals Ltd. under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards, ensuring every batch of Axinix meets consistent quality, safety, and efficacy requirements. |
How to Take Axinix (Axitinib)
Route: Oral, taken by mouth
Standard dose: 5mg taken orally twice daily (approximately 12 hours apart). Treatment is continued until disease progression or unacceptable toxicity.
Dose escalation: For patients who tolerate the starting dose with no adverse reactions above Grade 2 severity, whose blood pressure is not above 150/90 mmHg, and who are not receiving antihypertensive medication, the dose may be increased stepwise to 7mg twice daily and then to a maximum of 10mg twice daily.
Dose reduction: If side effects require it, the dose may be reduced stepwise to 3mg twice daily and then to 2mg twice daily. The 1mg tablet is used in combination with the 5mg tablet to achieve the exact required dose at each step.
With food: Can be taken with or without food. The tablets should be swallowed whole with a glass of water and must not be crushed or split.
If a dose is missed: If a dose is missed or vomiting occurs after taking a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual scheduled time.
CYP3A4 and CYP3A5 interactions: The dose should be reduced by approximately half (for example, from 5mg twice daily to 2mg to 3mg twice daily) when co-administering with strong CYP3A4 or CYP3A5 inhibitors such as ketoconazole. Conversely, strong CYP3A4 or CYP3A5 inducers may reduce Axitinib exposure and should be avoided where possible.
Hepatic impairment: No dose adjustment is required for mild hepatic impairment (Child-Pugh Class A). In moderate hepatic impairment (Child-Pugh Class B), the starting dose should be reduced to approximately half. Axinix has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and is not recommended in this group.
Renal impairment: No dose adjustment is required. However, caution is advised in patients with end-stage renal disease.
Paediatric use: The safety and efficacy of Axinix in children and adolescents below 18 years of age have not been established. No data are currently available.
Monitoring and Dosage Adjustments
Regular monitoring is essential during Axinix treatment. Your healthcare provider will closely monitor blood pressure, as hypertension is one of the most common effects of VEGFR inhibition and may require initiation or adjustment of antihypertensive therapy. Monitoring also includes assessment for proteinuria (protein in the urine), thyroid function (as hypothyroidism is a known effect), liver function tests, signs of bleeding or haemorrhage, and cardiac function. Your oncologist will guide dose titration decisions based on your individual tolerability, blood pressure readings, and overall clinical response. Report any new or worsening symptoms to your oncology team promptly.
Drug Interactions and Important Information
Avoid concomitant use of Axinix with strong CYP3A4 or CYP3A5 inhibitors such as ketoconazole, itraconazole, clarithromycin, and ritonavir, as these significantly increase Axitinib plasma concentrations and may worsen side effects. If a strong CYP3A4 inhibitor cannot be avoided, the Axinix dose should be reduced by approximately half.
Avoid concomitant use with strong CYP3A4 or CYP3A5 inducers such as rifampicin, phenytoin, carbamazepine, and St John’s Wort, as these can substantially reduce Axitinib plasma levels and decrease its anti-tumour effectiveness. Grapefruit and grapefruit juice should also be avoided. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Axinix.
Side Effects and Precautions
|
Common Side Effects Hypertension (high blood pressure) Diarrhoea Fatigue and asthenia Decreased appetite and weight loss Nausea and vomiting Dysphonia (voice changes or hoarseness) Palmar-plantar erythrodysaesthesia (hand-foot syndrome) Hypothyroidism (underactive thyroid) |
Serious Warnings and Precautions Haemorrhagic events including fatal bleeding. Do not use in patients with untreated brain metastases or recent active gastrointestinal bleeding. Arterial and venous thromboembolic events including stroke, heart attack, and pulmonary embolism. Use with caution in patients with a history of such events. Cardiac failure. Monitor cardiac function, especially in patients with existing heart conditions. Gastrointestinal perforation and fistula formation. Report any sudden or severe abdominal pain immediately. Impaired wound healing. Treatment should be stopped at least 24 hours before any planned surgery. Reversible posterior leukoencephalopathy syndrome (RPLS). Seek immediate medical attention for severe headache, seizures, confusion, or visual disturbances. Can cause harm to an unborn baby. Not recommended during pregnancy or breastfeeding. |
Who Should Use Axinix (Axitinib)?
Axinix is suitable for adult patients diagnosed with advanced renal cell carcinoma (kidney cancer). This includes patients who require second-line monotherapy after failure of one prior systemic treatment and patients receiving first-line combination therapy with an immune checkpoint inhibitor such as Pembrolizumab or Avelumab. It is prescribed and supervised by oncologists and specialist physicians experienced in the management of kidney cancer and anti-angiogenic therapies. A thorough assessment, including blood pressure evaluation, thyroid function, liver function, urinalysis for proteinuria, and review of all current medications, is required before initiating treatment.
Manufacturer: Beacon Pharmaceuticals Ltd.
Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh, and the number one oncology and specialty medicine company in the country. Beacon is the first company in Bangladesh to export cancer drugs and currently exports to Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified standards. Axinix is one of Beacon’s globally recognised oncology products, offering an affordable and bioequivalent alternative to Inlyta by Pfizer at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of oncology and specialty medications. We ensure Axinix (Axitinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Axinix (Axitinib) from Mediaid Pharmacy?
Axinix represents a major advancement in the targeted treatment of advanced kidney cancer. As the generic equivalent of Inlyta by Pfizer, it delivers the same active ingredient, Axitinib, with the same proven anti-angiogenic VEGFR inhibition mechanism at a dramatically more affordable price. Manufactured by the internationally trusted Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy, Axinix gives patients worldwide access to high-quality targeted cancer therapy without the financial burden of brand-name alternatives. For patients and oncologists seeking a proven, affordable, and accessible Axitinib option with worldwide delivery, Axinix from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Axinix (Axitinib)
What is Axinix (Axitinib) used for?
Axinix (Axitinib) is a selective VEGFR tyrosine kinase inhibitor used to treat advanced renal cell carcinoma (kidney cancer) in adults. It is approved as a second-line monotherapy after failure of one prior systemic treatment, and as a first-line treatment in combination with immune checkpoint inhibitors such as Pembrolizumab or Avelumab. It works by cutting off the blood supply that tumours need to grow and spread.
How should I take Axinix (Axitinib)?
Axinix is taken orally twice daily, approximately 12 hours apart, with or without food. The standard starting dose is 5mg twice daily. Your oncologist may increase the dose stepwise up to 10mg twice daily if well tolerated, or reduce it to as low as 2mg twice daily if side effects require management. Always follow your prescribing physician’s exact instructions.
What strengths and pack sizes is Axinix (Axitinib) available in?
Axinix is available in 1mg and 5mg film-coated tablets. It is supplied in pots of 180 tablets and pots of 60 tablets. The two strengths allow flexible dose adjustments, enabling your oncologist to precisely tailor the dose to achieve the best balance of efficacy and tolerability for your individual needs.
Is Axinix the same as Inlyta (Axitinib by Pfizer)?
Yes. Axinix is the generic equivalent of Inlyta. Both contain the same active ingredient, Axitinib, in the same dosage form and strengths. Axinix is manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh and delivers the same targeted anti-angiogenic action as Inlyta at a significantly lower cost, making it a more accessible option for patients worldwide.
What are the side effects of Axinix (Axitinib)?
Common side effects include hypertension, diarrhoea, fatigue, decreased appetite, nausea, voice changes, hand-foot syndrome, and hypothyroidism. Serious but less common risks include haemorrhagic events, blood clots, cardiac failure, gastrointestinal perforation, and reversible posterior leukoencephalopathy syndrome. Always consult your physician for a complete assessment of your individual risks and benefits before starting treatment.
Can Axinix be used with immunotherapy drugs?
Yes. Axinix is approved for first-line use in combination with the immune checkpoint inhibitors Pembrolizumab (anti-PD-1) and Avelumab (anti-PD-L1) in advanced renal cell carcinoma. These combinations have demonstrated superior outcomes compared with single-agent targeted therapy and are now a standard of care in first-line kidney cancer treatment.
Is Axinix (Axitinib) safe during pregnancy or breastfeeding?
No. Axinix can harm an unborn baby and is not recommended during pregnancy or breastfeeding. Both women and men of reproductive potential should use effective contraception during treatment and for a period after the final dose, as advised by their physician. Please inform your doctor before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Axinix (Axitinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Axinix (Axitinib) 1mg and 5mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Axinix (Axitinib) 1mg and 5mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: mediaidpharma66@gmail.com
